This is How Aspira Women’s Health is Detecting the Risk of Ovarian Cancer Early

With its lack of early diagnostics and greater than 50% mortality rate, ovarian cancer impacts enormous costs to women and society as a whole. But there is light at the end of the tunnel, thanks to Valerie Palmieri, a force to be reckoned with and the featured guest on this episode of Busine$$ of the V. As President and CEO at Aspira Women’s Health, she is not only overseeing the development of blood-based solutions that will improve gynecologic health outcomes, she is also fighting mightily to ensure that these non-invasive blood based risk assessment tools are available to women across the socio-economic spectrum.

Ovarian cancer is the fifth most common gender-specific cancer and, says Valerie, the most grueling of them all. But Aspira’s FDA-cleared bio-informatics products are able to detect with a high level of accuracy,  the risk for malignancy in pelvic masses – a breakthrough compared with the limited ovarian cancer diagnostics available to date. The company has also recently launched Aspira GenetiXSM testing, which offers both targeted and comprehensive genetic testing options. The trick is to predict personalized risk of this evasive cancer as early as possible.

Valerie shares her journey both personally, as a scientist and executive in the startup diagnostic space, and as a vigorous advocate for equal access to ovarian cancer diagnostics. A formidable leader, she is driving awareness for Aspira, building a niche for the company within the life sciences sector and fighting to save lives (along with enormous private and governmental insurance expense). She offers advice for up-and-coming life sciences entrepreneurs and a glimpse of a future in which genetic markers will play a big role in ensuring women’s health. As Rachel notes after reviewing Aspira’s study results: “The numbers are life-changing!”

Enjoy this hopeful conversation with a stand-out femtech pioneer! Visit https://businessofthev.com for more episodes, show notes and more.